Griseofulvin Tablets and Xenleta (Lefamulin Injection)
Determining the interaction of Griseofulvin Tablets and Xenleta (Lefamulin Injection) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. The interaction has not been studied with other, less potent inducers. MANAGEMENT: The potential for diminished pharmacologic effects of lefamulin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. The interaction has not been studied with other, less potent inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of lefamulin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: griseofulvin
Brand name: Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
Synonyms: Griseofulvin
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Xenleta, Xenleta (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Griseofulvin Tablets-Xenleta (Lefamulin Tablets)
- Griseofulvin Tablets-Xeomin
- Griseofulvin Tablets-Xerava
- Griseofulvin Tablets-Xerese
- Griseofulvin Tablets-Xerese Cream
- Griseofulvin Tablets-Xermelo
- Xenleta (Lefamulin Injection)-Griseofulvin Ultramicrosize Tablets
- Xenleta (Lefamulin Injection)-Guaiatussin AC
- Xenleta (Lefamulin Injection)-Guaifen DAC
- Xenleta (Lefamulin Injection)-Guaifenesin AC Liquid
- Xenleta (Lefamulin Injection)-Guaifenesin and Codeine
- Xenleta (Lefamulin Injection)-Guaifenesin and Dextromethorphan Capsules and Tablets